These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22121482)

  • 21. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
    Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
    Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Demonstration of focal physiologic in-vivo somatostatin receptor expression in the caput epididymis of the testes on
    Parihar AS; Sood A; Sood A; Gulati A; Mittal BR
    Asia Ocean J Nucl Med Biol; 2020; 8(2):132-135. PubMed ID: 32715001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Head-to-Head Comparison of
    Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of Ga
    Plaza López PJ; Suarez Pinera M; Mestre Fusco A; Domenech Brasero B; Pifarré Muntané P; Rivera Codias E
    Endocrinol Diabetes Nutr (Engl Ed); 2020 Dec; 67(10):636-642. PubMed ID: 32317147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology.
    Salavati A; Prasad V; Schneider CP; Herbst R; Baum RP
    Ann Nucl Med; 2012 May; 26(4):365-9. PubMed ID: 22361935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.
    Basu S; Ranade R; Thapa P
    World J Nucl Med; 2016; 15(1):38-43. PubMed ID: 26912977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of Somatostatin Receptor 1-5 Expression, [
    Majala S; Vesterinen T; Seppänen H; Mustonen H; Sundström J; Schalin-Jäntti C; Gullichsen R; Schildt J; Kemppainen J; Arola J; Kauhanen S
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
    Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
    J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Kulkarni HR; Schuchardt C; Baum RP
    Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
    Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
    Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT.
    Majala S; Seppänen H; Kemppainen J; Sundström J; Schalin-Jäntti C; Gullichsen R; Schildt J; Mustonen H; Vesterinen T; Arola J; Kauhanen S
    EJNMMI Res; 2019 Dec; 9(1):116. PubMed ID: 31872324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
    Kabasakal L; Demirci E; Ocak M; Decristoforo C; Araman A; Ozsoy Y; Uslu I; Kanmaz B
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using
    Ilan E; Velikyan I; Sandström M; Sundin A; Lubberink M
    J Nucl Med; 2020 Feb; 61(2):217-221. PubMed ID: 31302632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
    Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
    J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?
    Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H
    Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paget's Disease Mimicking Bone Metastasis in a Patient with Neuroendocrine Tumor on
    Gezer NS; Balcı A; Özdoğan Ö; Özaksoy D
    J Belg Soc Radiol; 2016 Jul; 100(1):66. PubMed ID: 30151468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.
    Baum RP; Kulkarni HR; Carreras C
    Semin Nucl Med; 2012 May; 42(3):190-207. PubMed ID: 22475428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism.
    Prasad V; Ambrosini V; Alavi A; Fanti S; Baum RP
    PET Clin; 2007 Jul; 2(3):351-75. PubMed ID: 27158016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.